HIV News and Research RSS Feed - HIV News and Research

Scientists find gorilla origins in two human AIDS virus lineages

Scientists find gorilla origins in two human AIDS virus lineages

Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to an international team of scientists from the Perelman School of Medicine at the University of Pennsylvania, the University of Montpellier, the University of Edinburgh, and others. [More]
New study examines risk factors for use of synthetic marijuana among teens

New study examines risk factors for use of synthetic marijuana among teens

Synthetic cannabinoids ("synthetic marijuana"), with names like Spice, K2, Scooby Doo and hundreds of others, are often sold as a "legal" alternative to marijuana. Often perceived as a safe legal alternative to illicit drug use, synthetic marijuana use was associated with 11,561 reports of poisonings in the United States between January 2009 and April 2012. [More]
Nottingham researchers developing mobile phone app that could help identify premature babies

Nottingham researchers developing mobile phone app that could help identify premature babies

A mobile phone app that will identify babies born prematurely in the developing world is being developed by researchers at The University of Nottingham. [More]
Findings may explain why HIV cure strategies have failed

Findings may explain why HIV cure strategies have failed

A major hurdle to curing people of HIV infection is the way the virus hides in a reservoir composed primarily of dormant immune cells. [More]
WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi applauds TaiMed for receiving FDA breakthrough therapy designation for ibalizumab

WuXi PharmaTech (Cayman) Inc., a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, congratulates our partner TaiMed Biologics for receiving breakthrough therapy designation from the U.S. FDA for ibalizumab (TMB355). [More]

Mylan acquires non-U.S. developed markets specialty and branded generics business from Abbott

Mylan N.V. and Mylan Inc. today announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
New research reveals that HIV latency is controlled by the virus itself

New research reveals that HIV latency is controlled by the virus itself

New research from the Gladstone Institutes for the first time provides strong evidence that HIV latency is controlled not by infected host cells, but by the virus itself. This fundamentally changes how scientists perceive latency, presenting it as an evolutionarily advantageous phenomenon rather than a biological accident. [More]
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
UMass Amherst biologist partners with Chinese scientist to develop novel drug platform

UMass Amherst biologist partners with Chinese scientist to develop novel drug platform

Margaret Riley, an evolutionary biologist at the University of Massachusetts Amherst and pioneer in fighting antibiotic-resistant bacteria, announced this week that she is partnering with a Chinese scientist to develop a new drug platform, pheromonicins. The Chinese government is committing $400 million per year to support the newly created Pheromonicin Institute of Beijing. [More]
Study shows how financial incentives can influence some HIV-positive patients in clinical settings

Study shows how financial incentives can influence some HIV-positive patients in clinical settings

A new study by the HIV Prevention Trials Network shows that some HIV-positive patients were motivated by financial incentives to take their HIV antiretroviral therapy (ART) medication regularly and maintain control of their HIV - enhancing their own health benefits and reducing the chance of passing the virus on to others. [More]
bioLytical receives FDA approval for INSTI HIV Antibody Test

bioLytical receives FDA approval for INSTI HIV Antibody Test

bioLytical Laboratories Inc., a leading manufacturer of point-of-care rapid diagnostic tests, announced today that it has received U.S. Food and Drug Administration approval of its INSTI HIV Antibody Test for use in detecting antibodies to HIV type 2 (HIV-2). [More]

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

The Medicines Patent Pool announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. [More]
Bayer expands patient assistance program for intrauterine devices

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria. [More]
Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. [More]
Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western Reserve University dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice. [More]
Neuronetrix announces FDA approval of COGNISION System for clinical use

Neuronetrix announces FDA approval of COGNISION System for clinical use

Neuronetrix today announced that it has received 510(k) clearance (K141316) from the United States Food and Drug Administration to market the COGNISION System for clinical use. [More]
Betaretrovirus may infect patients with primary biliary cirrhosis

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC). [More]
Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus. [More]
Scientists develop promising new HIV vaccine agent

Scientists develop promising new HIV vaccine agent

In a study that involved researchers from over a dozen institutions, the anti-HIV agent protected monkeys from every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) for at least 34 weeks. [More]